Publications
2022 OHE Annual Report to the Charity Commission
30 November 2023
This is the sixth report to the Charity Commission for England and Wales since becoming a registered charity in December 2016.
Capturing the Broader Value of Antibiotics
23 November 2023
The value of antibiotics often extends beyond what HTA captures. The STEDI framework aims to capture that broader value and our report outlines a roadmap to realising its full potential.
Innovation for Health System Efficiency and Improvement
20 November 2023
In this report, commissioned and funded by Gilead, we explore the role of innovation in developing healthcare system efficiency amid post-pandemic challenges.
Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
8 November 2023
NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently needed antibiotics.
Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
2 November 2023
New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing compensation regardless of sales volume.
Reimagining Prevention for a Healthier, More Prosperous Society
12 October 2023
In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary measures, can help to reduce ill health, improve healthcare capacity, and increase wider economic growth.
NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
18 September 2023
In this report, we explore the potential impact of the National Institute of Health and Care Excellence (NICE) decision outcomes on healthcare decision-making in 12 countries across the globe (Australia, Brazil, Canada, France, Italy, Israel, Japan, South Korea, Poland, Saudi Arabia, Sweden, and the United Arab Emirates). We used quantitative and qualitative methods to estimate the level of impact and potential underlying mechanisms.
Are Recommendations for HTA of Gene Therapies Being Achieved?
11 September 2023
In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.
The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society
18 July 2023
The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS and wider society. The foreword has been provided by Angela Gibbons, patient and HS advocate.
This project has been organised and funded by Novartis Pharmaceuticals UK Ltd, with support from M+F Health. The report is informed by input from experts working in HS, including leading clinicians.